argenx SE at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:00PM GMT
James Gordon JPMorgan Chase&Co.-Analyst

Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, it's my pleasure to introduce the argenx presentation, and you're going to hear from argenx CEO, Tim Hauwermeiren. And we have the breakout in here as well, so 20 minutes presentation and then time for your questions. So thanks a lot for joining us today, Tim.

Tim Hauwermeiren argenx SE-CEO

Good morning, everyone, and warm welcome to the argenx implementation. And whilst we take a look at the forward-looking statements, James, I would like to thank you for hosting us today at this wonderful conference.

We at argenx, we're on a bold journey, a journey to transform autoimmunity. Actually, we want to take autoimmunity away from surgery and blunt chemotherapy into precision medication, where we basically nail with precision tools, specific molecular pathways, which drive disease, offering a radically different benefit risk profile to patients, a transformative benefit to patients.

And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot